Breast cancer is subdivided into immunohistochemistry (IHC) subtypes based on the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor II (HER2). This evidence concerns the gene ESR1 and breast carcinoma.